Portal de Periódicos da CAPES

Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS

2021; Research Square (United States); Linguagem: Inglês

10.21203/rs.3.rs-279400/v1

Daniel Prieto‐Alhambra, Kristin Kostka, Talita Duarte‐Salles, Albert Prats‐Uribe, Anthony G. Sena, Andrea Pistillo, Sara Khalid, Lana Yin Hui Lai, Asieh Golozar, Thamir M. Alshammari, Dalia Dawoud, Fredrik Nyberg, Adam B. Wilcox, Alan Andryc, Andrew E. Williams, Anna Ostropolets, Carlos Areia, Chi Young Jung, Christopher A. Harle, Christian Reich, Clair Blacketer, Daniel R. Morales, David A. Dorr, Edward Burn, Elena Roel, Eng Hooi Tan, Evan Minty, Frank DeFalco, Gabriel de Maeztu, Gigi Lipori, Heba Alghoul, Hong Zhu, Jason Thomas, Jiang Bian, Jimyung Park, Jordi Martínez Roldán, Jose Posada, Juan M. Banda, Juan Pablo Horcajada, Julianna Kohler, Karishma Shah, Karthik Natarajan, Kristine E. Lynch, Li Liu, Lisa M. Schilling, Martina Recalde, Henry M. Spotnitz, Mengchun Gong, Michael E. Matheny, Neus Valveny, Nicole G. Weiskopf, Nigam H. Shah, Osaid Alser, Paula Casajust, R. W. Park, Robert Schuff, Sarah Seager, Scott L. DuVall, Seng Chan You, Seok Young Song, Sergio Fernández‐Bertolín, Stephen Fortin, Tanja Magoč, Thomas Falconer, Vignesh Subbian, Vojtech Huser, Waheed‐Ul‐Rahman Ahmed, W. Carter, Yin Guan, Yankuic Galvan, Xing He, Peter R. Rijnbeek, George Hripcsak, Patrick Ryan, Marc A. Suchard,

COVID-19 epidemiological studies

Abstract Background: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response [1,2]. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) [3] Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD. Methods: We conducted a descriptive cohort study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11 th June 2020 and are iteratively updated via GitHub [4]. Findings: We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19 , and 113,627 hospitalized with COVID-19 requiring intensive services . All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts, and are available in an interactive website: https://data.ohdsi.org/Covid19CharacterizationCharybdis/. Interpretation: CHARYBDIS findings provide benchmarks that contribute to our understanding of COVID-19 progression, management and evolution over time. This can enable timely assessment of real-world outcomes of preventative and therapeutic options as they are introduced in clinical practice.